UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanisms of receptor tyrosine kinase activation in cancer

Molecular cancer, 2018-02, Vol.17 (1), p.58-13, Article 58

2018

Volltextzugriff (PDF)

Perioperative Immunotherapy — A KEY toward Improved Outcomes for Early-Stage Lung Cancer?

The New England journal of medicine, 2023-08, Vol.389 (6), p.560-561

Lovly, Christine M.

2023

Volltextzugriff (PDF)

Expanding Horizons for Treatment of Early-Stage Lung Cancer

The New England journal of medicine, 2022-05, Vol.386 (21), p.2050-2051

Lovly, Christine M.

2022

Volltextzugriff (PDF)

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

Clinical cancer research, 2014-05, Vol.20 (9), p.2249-2256

2014

Volltextzugriff (PDF)

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

Clinical cancer research, 2015-10, Vol.21 (19), p.4270-4277

2015

Volltextzugriff (PDF)

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine

Clinical cancer research, 2015-05, Vol.21 (10), p.2227-2235

2015

Volltextzugriff (PDF)

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Nature communications, 2016-01, Vol.7 (1), p.10582-10582, Article 10582

2016

Volltextzugriff (PDF)

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

Journal of clinical oncology, 2018-04, Vol.36 (12), p.1199-1206

2018

Volltextzugriff (PDF)

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions

Cancer discovery, 2014-08, Vol.4 (8), p.889-895

2014

Volltextzugriff (PDF)

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Journal of clinical oncology, 2012-03, Vol.30 (8), p.863-870

2012

Volltextzugriff (PDF)

Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors

Clinical cancer research, 2014-12, Vol.20 (23), p.5898-5907

2014

Volltextzugriff (PDF)

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Clinical cancer research, 2018-06, Vol.24 (12), p.2771-2779

2018

Volltextzugriff (PDF)

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Cancer research (Chicago, Ill.), 2017-06, Vol.77 (11), p.2990-3000

2017

Volltextzugriff (PDF)

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties

Molecular cancer research, 2018-11, Vol.16 (11), p.1724-1736

2018

Volltextzugriff (PDF)

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

PloS one, 2012-04, Vol.7 (4), p.e35309-e35309

2012

Volltextzugriff (PDF)

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Clinical cancer research, 2019-06, Vol.25 (11), p.3341-3351

2019

Volltextzugriff (PDF)

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance

Science translational medicine, 2012-02, Vol.4 (120), p.120ps2

2012

Volltextzugriff (PDF)

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Clinical cancer research, 2012-09, Vol.18 (17), p.4682-4690

2012

Volltextzugriff (PDF)

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Cancer immunology research, 2016-11, Vol.4 (11), p.959-967

2016

Volltextzugriff (PDF)

Challenges in the implementation of ultrasensitive liquid biopsy approaches in precision oncology

Journal for immunotherapy of cancer, 2023-06, Vol.11 (6), p.e006793

2023

Volltextzugriff (PDF)

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

Cancer research (Chicago, Ill.), 2016-01, Vol.76 (2), p.305-318

2016

Volltextzugriff (PDF)

Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors

Modern pathology, 2015-05, Vol.28 (5), p.732-739

2015

Volltextzugriff (PDF)

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years

Journal of clinical oncology, 2024-10, Vol.42 (29), p.3383-3386

Lovly, Christine M

2024

Volltextzugriff (PDF)

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2022-07, Vol.119 (30), p.e2206588119

2022

Volltextzugriff (PDF)

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Clinical cancer research, 2011-12, Vol.17 (23), p.7394-7401

2011

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(155)

Publikationsform

Artikel
(188)
Berichte
(1)

Sprache

Englisch
(189)

Erscheinungsjahr

n.n

Thema

Science & Technology
(109)
Humans
(104)
Life Sciences & Biomedicine
(101)
Oncology
(84)
Lung Neoplasms - Drug Therapy
(45)
Lung Neoplasms - Genetics
(40)
Mutation
(38)
Female
(32)
Male
(30)
Lung Neoplasms - Pathology
(28)
Middle Aged
(27)
Aged
(24)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(24)
Protein Kinase Inhibitors - Therapeutic Use
(24)
Carcinoma, Non-Small-Cell Lung - Genetics
(22)
Protein Kinase Inhibitors - Pharmacology
(21)
Adult
(20)
Cell Line, Tumor
(20)
Lung Cancer
(19)
Animals
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Mechanisms of receptor tyrosine kinase activation in cancer

Perioperative Immunotherapy — A KEY toward Improved Outcomes for Early-Stage Lung Cancer?

Expanding Horizons for Treatment of Early-Stage Lung Cancer

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Challenges in the implementation of ultrasensitive liquid biopsy approaches in precision oncology

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Suchergebnisse filtern